Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new antibody-drug conjugate (ADC) to its pipeline. Roche, which put ...

Roche share price performance has been flattish of late, but that's good for some relative outperformance as the pharmaceutical sector has underperformed. Roche has seen further clinical setbacks ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Roche has a big problem. With competition threatening some of its older and most lucrative biologic drugs ...

Nevertheless, it’s Roche that’s been tipped to stand at the front of the pack when it comes to prescription sales overall in 2025. Evaluate acknowledged that Roche’s projected position as ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui. Experts weighed in on the potential implications and lessons from two ...

Sir Brian Roche says there is a concern about the level of analysis given to Treaty "breaches". Photo / Marty Melville There are too many meetings in the public service, too many layers of ...

Thomas Roche, 27, was last seen at 12:30 BST on 6 October when he left the flat he shared with his girlfriend in Chester Close, Bletchley, Buckinghamshire, for a cigarette. His sister Carly Roche ...

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...

Those include Fibrogen's pamrevlumab and Roche's PRM-151 in phase 3 – as well as Novartis' ianalumab, Galecto Biotech's TD-139/, Bristol-Myers Squibb's CC-90001 and BMS-986278, and Liminal ...